Adagene (ADAG) vs ALX Oncology (ALXO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed ALX Oncology (ALXO) over the past year, gaining 42.2% versus a loss of 40.1%. Over five years, ADAG leads with a -76.2% price change compared with -98.0% for ALXO. Adagene is the larger company by market cap ($185.3 million vs $172.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | ALXO |
|---|---|---|
| Share price | $2.76 | $1.25 |
| Market cap | $185.32M | $172.85M |
| 1-day change | -0.72% | +5.93% |
| YTD return | +47.09% | +4.42% |
| 1-year return | +42.20% | -40.10% |
| 5-year return | -76.24% | -98.00% |
| EPS (TTM) | $-0.37 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $2.66 |
| 52-week low | $1.30 | $1.05 |
| Distance from 52-week high | -43.09% | -53.01% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +259.06% | +268.00% |
| Average volume | 244.76K | 1.04M |
| Shares outstanding | 67.14M | 138.28M |
| Employees | 128 | 48 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed ALXO by 82.3 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
ADAG vs ALXO FAQ
Which is bigger, Adagene or ALX Oncology?
Adagene (ADAG) is larger, with a market capitalization of $185.32M compared with $172.85M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ADAG or ALXO?
ADAG returned +42.20% over the past 12 months, compared with -40.10% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and ALX Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.